

Transcript and metabolite analysis of the effects of tamoxifen on the inhibition of fatty acid synthesis in the presence of heparin

FASEB Journal

19, 1108-1119

DOI: 10.1096/fj.04-3196com

Citation Report

#	ARTICLE	IF	CITATIONS
1	Metabolomic approaches to phenotype characterization and applications to complex diseases. Expert Review of Molecular Diagnostics, 2006, 6, 575-585.	3.1	84
2	Diet and Cancer: Facts and Controversies. Nutrition and Cancer, 2006, 56, 216-224.	2.0	56
4	Targeting Fatty Acid Synthase in Breast and Endometrial Cancer: An Alternative to Selective Estrogen Receptor Modulators?. Endocrinology, 2006, 147, 4056-4066.	2.8	102
5	Does HLA-B27 influence the monocyte inflammatory response to lipopolysaccharide?. Rheumatology, 2006, 46, 232-237.	1.9	13
6	Ablation of PGC-1 β Results in Defective Mitochondrial Activity, Thermogenesis, Hepatic Function, and Cardiac Performance. PLoS Biology, 2006, 4, e369.	5.6	249
7	Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver. Journal of Lipid Research, 2006, 47, 2223-2232.	4.2	52
8	Tamoxifen-Induced Anorexia Is Associated With Fatty Acid Synthase Inhibition in the Ventromedial Nucleus of the Hypothalamus and Accumulation of Malonyl-CoA. Diabetes, 2006, 55, 1327-1336.	0.6	143
9	Designing experiments that aid in the identification of regulatory networks. Briefings in Functional Genomics & Proteomics, 2006, 4, 331-342.	3.8	4
10	Global metabolic profiling and its role in systems biology to advance personalized medicine in the 21st Century. Expert Review of Molecular Diagnostics, 2007, 7, 247-259.	3.1	45
11	C75, a Fatty Acid Synthase (FAS) Inhibitor. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2007, 1, 53-62.	0.6	3
13	INTEGRATED NMR-BASED METABONOMIC INVESTIGATION OF EARLY METABOLIC EFFECTS OF ETHYLENE GLYCOL MONOMETHYL ETHER (EGME) ON MALE REPRODUCTIVE ORGANS IN RATS. Journal of Toxicological Sciences, 2007, 32, 515-528.	1.5	10
15	Peripheral tissue-brain interactions in the regulation of food intake. Proceedings of the Nutrition Society, 2007, 66, 131-155.	1.0	74
16	Tamoxifen Inhibits Topoisomerases, Depletes Mitochondrial DNA, and Triggers Steatosis in Mouse Liver. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 526-535.	2.5	131
17	Appetite Regulation: An Overview. Thyroid, 2007, 17, 433-445.	4.5	100
18	Genomic Profiling of Liver Injury. , 0, , 465-488.		3
20	Hypothalamic fatty acid metabolism: A housekeeping pathway that regulates food intake. BioEssays, 2007, 29, 248-261.	2.5	127
21	Gene expression profiling reveals underlying molecular mechanisms of the early stages of tamoxifen-induced rat hepatocarcinogenesis. Toxicology and Applied Pharmacology, 2007, 225, 61-69.	2.8	26
22	TAMOXIFEN PROTECTS AGAINST 17 β -ETHYNYLESTRADIOL-INDUCED LIVER DAMAGE AND THE DEVELOPMENT OF UROGENITAL PAPILLAE IN THE RAINBOW DARTER (ETHEOSTOMA CAERULEUM). Environmental Toxicology and Chemistry, 2007, 26, 1879.	4.3	14

#	ARTICLE	IF	CITATIONS
23	Application of metabolic flux analysis to identify the mechanisms of free fatty acid toxicity to human hepatoma cell line. <i>Biotechnology and Bioengineering</i> , 2008, 99, 399-410.	3.3	44
24	Hypothalamic Fatty Acid Metabolism Mediates the Orexigenic Action of Ghrelin. <i>Cell Metabolism</i> , 2008, 7, 389-399.	16.2	417
25	Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis. <i>Pharmacological Reviews</i> , 2008, 60, 311-357.	16.0	346
26	Fatty Acid Synthase: A Target for the Reversal of Liver Steatosis. <i>Current Enzyme Inhibition</i> , 2008, 4, 100-108.	0.4	1
28	Brain lipogenesis and regulation of energy metabolism. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2008, 11, 483-490.	2.5	22
29	Hypothalamic Lipids and the Regulation of Energy Homeostasis. <i>Obesity Facts</i> , 2009, 2, 1-1.	3.4	24
30	<i>In vitro</i> assay for drug-induced hepatosteatosis using rat primary hepatocytes, a fluorescent lipid analog and gene expression analysis. <i>Journal of Applied Toxicology</i> , 2009, 29, 356-363.	2.8	27
31	Effects of estrogen and androgen deprivation on the progression of non-alcoholic steatohepatitis (NASH) in male Sprague-Dawley rats. <i>Hepatology Research</i> , 2009, 39, 910-920.	3.4	13
32	Enhanced steatosis by nuclear receptor ligands: A study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. <i>Chemico-Biological Interactions</i> , 2010, 184, 376-387.	4.0	74
33	Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. <i>Hepatology</i> , 2010, 52, 1258-1265.	7.3	95
34	A Role for Sp1 in Transcriptional Regulation of Phosphatidylethanolamine N-Methyltransferase in Liver and 3T3-L1 Adipocytes. <i>Journal of Biological Chemistry</i> , 2010, 285, 11880-11891.	3.4	24
35	Identification of Noninvasive Biomarkers for Alcohol-Induced Liver Disease Using Urinary Metabolomics and the Ppara-null Mouse. <i>Journal of Proteome Research</i> , 2010, 9, 4176-4188.	3.7	57
36	Gene expression profiling of murine hepatic steatosis induced by tamoxifen. <i>Toxicology Letters</i> , 2010, 199, 416-424.	0.8	32
38	The mechanistic basis for the induction of hepatic steatosis by xenobiotics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 949-965.	3.3	23
39	Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies. <i>Toxicology</i> , 2011, 279, 10-18.	4.2	51
40	Ablation of PGC1 beta prevents mTOR dependent endoplasmic reticulum stress response. <i>Experimental Neurology</i> , 2012, 237, 396-406.	4.1	20
41	A Myriad of Pathways to NASH. <i>Clinics in Liver Disease</i> , 2012, 16, 525-548.	2.1	37
42	Effect of chronic administration of tamoxifen and/or estradiol on feeding behavior, palatable food and metabolic parameters in ovariectomized rats. <i>Physiology and Behavior</i> , 2013, 119, 17-24.	2.1	34

#	ARTICLE	IF	CITATIONS
43	The Role of Estrogens in Control of Energy Balance and Glucose Homeostasis. <i>Endocrine Reviews</i> , 2013, 34, 309-338.	20.1	875
44	Adverse Effects of Hormones and Hormone Antagonists on the Liver. , 2013, , 605-619.		9
45	Effects of Neonatal Programming on Hypothalamic Mechanisms Controlling Energy Balance. <i>Hormone and Metabolic Research</i> , 2013, 45, 935-944.	1.5	19
46	Testosterone Replacement Ameliorates Nonalcoholic Fatty Liver Disease in Castrated Male Rats. <i>Endocrinology</i> , 2014, 155, 417-428.	2.8	64
47	The Effect and Mechanism of Tamoxifen-Induced Hepatocyte Steatosis in Vitro. <i>International Journal of Molecular Sciences</i> , 2014, 15, 4019-4030.	4.1	55
48	Drug-Induced Hepatic Steatosis. <i>Seminars in Liver Disease</i> , 2014, 34, 205-214.	3.6	80
49	The IGF2 mRNA binding protein p62/IGF2BP2-2 induces fatty acid elongation as a critical feature of steatosis. <i>Journal of Lipid Research</i> , 2014, 55, 1087-1097.	4.2	42
50	SEURAT-1 liver gold reference compounds: a mechanism-based review. <i>Archives of Toxicology</i> , 2014, 88, 2099-2133.	4.2	26
51	Genotoxic, epigenetic, and transcriptomic effects of tamoxifen in mouse liver. <i>Toxicology</i> , 2014, 325, 12-20.	4.2	8
52	Uridine prevents tamoxifen-induced liver lipid droplet accumulation. <i>BMC Pharmacology & Toxicology</i> , 2014, 15, 27.	2.4	30
55	Selective Estrogen Receptor Modulator-Associated Nonalcoholic Fatty Liver Disease Improved Survival in Patients With Breast Cancer. <i>Medicine (United States)</i> , 2015, 94, e1718.	1.0	10
56	Tetracyclines Disturb Mitochondrial Function across Eukaryotic Models: A Call for Caution in Biomedical Research. <i>Cell Reports</i> , 2015, 10, 1681-1691.	6.4	385
57	Tetracycline Antibiotics Impair Mitochondrial Function and Its Experimental Use Confounds Research. <i>Cancer Research</i> , 2015, 75, 4446-4449.	0.9	112
58	Metabolic Flux Distribution during Defatting of Steatotic Human Hepatoma (HepG2) Cells. <i>Metabolites</i> , 2016, 6, 1.	2.9	42
59	Regulation of type 2 diabetes by helminth-induced Th2 immune response. <i>Journal of Veterinary Medical Science</i> , 2016, 78, 1855-1864.	0.9	20
60	ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 604-614.	2.5	28
61	The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways. <i>Critical Reviews in Toxicology</i> , 2016, 46, 138-152.	3.9	76
62	Effect of selective estrogen receptor modulators on metabolic homeostasis. <i>Biochimie</i> , 2016, 124, 92-97.	2.6	37

#	ARTICLE	IF	CITATIONS
63	The effect of selective estrogen receptor modulators on type 2 diabetes onset in women: Basic and clinical insights. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 773-779.	2.3	27
64	(â~)-UB006: A new fatty acid synthase inhibitor and cytotoxic agent without anorexic side effects. <i>European Journal of Medicinal Chemistry</i> , 2017, 131, 207-221.	5.5	12
65	Selective Activation of Estrogen Receptor Î± Activation Function-1 Is Sufficient to Prevent Obesity, Steatosis, and Insulin Resistance in Mouse. <i>American Journal of Pathology</i> , 2017, 187, 1273-1287.	3.8	38
66	Estradiol effects on hypothalamic AMPK and BAT thermogenesis: A gateway for obesity treatment?. , 2017, 178, 109-122.		53
67	Drug-induced steatohepatitis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 193-204.	3.3	47
68	Biomarker discovery for drug-induced phospholipidosis: phenylacetyl glycine to hippuric acid ratio in urine and plasma as potential markers. <i>Biomarkers</i> , 2017, 22, 178-188.	1.9	9
69	Leptin resistance during pregnancy is also exerted at the peripheryâ€. <i>Biology of Reproduction</i> , 2018, 98, 654-663.	2.7	9
70	Evaluation of progressive hepatic histopathology in long-term tamoxifen therapy. <i>Pathology Research and Practice</i> , 2018, 214, 2115-2120.	2.3	10
71	Selective Liver Estrogen Receptor Î± Modulation Prevents Steatosis, Diabetes, and Obesity Through the Anorectic Growth Differentiation Factor 15 Hepatokine in Mice. <i>Hepatology Communications</i> , 2019, 3, 908-924.	4.3	25
72	Tamoxifen affects the histology and hepatopancreatic lipid metabolism of swimming crab <i>Portunus trituberculatus</i> . <i>Aquatic Toxicology</i> , 2019, 213, 105220.	4.0	12
73	NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. <i>Endocrinology</i> , 2020, 161, .	2.8	94
74	Functional metabolomics using UPLC-Q/TOF-MS combined with ingenuity pathway analysis as a promising strategy for evaluating the efficacy and discovering amino acid metabolism as a potential therapeutic mechanism-related target for geniposide against alcoholic liver disease. <i>RSC Advances</i> , 2020, 10, 2677-2690.	3.6	37
76	Effect of Rosa canina Distilled Water on Tamoxifen-treated Male Wistar Rats. <i>Pakistan Journal of Biological Sciences</i> , 2020, 23, 173-180.	0.5	7
77	Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update. <i>Biomedicines</i> , 2022, 10, 194.	3.2	9
78	Preparation of Active Peptides from <i>Camellia vietnamensis</i> and Their Metabolic Effects in Alcohol-Induced Liver Injury Cells. <i>Molecules</i> , 2022, 27, 1790.	3.8	4
79	Mitochondria as the Target of Hepatotoxicity and Drug-Induced Liver Injury: Molecular Mechanisms and Detection Methods. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3315.	4.1	33
80	Integration of Metabolomics and Transcriptomics Reveals Major Pathways of Threonine Metabolism Involved in Alcoholic Liver Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
81	Tamoxifen induced hepatic steatosis in high-fat feeding rats through SIRT1-Foxo1 suppression and LXR-SREBP1c activation. <i>Toxicology Research</i> , 2022, 11, 673-682.	2.1	3

#	ARTICLE	IF	CITATIONS
82	Fatostatin inhibits SREBP2-mediated cholesterol uptake via LDLR against selective estrogen receptor $\hat{\pm}$ modulator-induced hepatic lipid accumulation. <i>Chemico-Biological Interactions</i> , 2022, 365, 110091.	4.0	3
83	Time to Change: A Systems Pharmacology Approach to Disentangle Mechanisms of Drug-Induced Mitochondrial Toxicity. <i>Pharmacological Reviews</i> , 2023, 75, 463-486.	16.0	3
84	Administration of Secretome Derived from Human Mesenchymal Stem Cells Induces Hepatoprotective Effects in Models of Idiosyncratic Drug-Induced Liver Injury Caused by Amiodarone or Tamoxifen. <i>Cells</i> , 2023, 12, 636.	4.1	2
85	Short-term tamoxifen administration improves hepatic steatosis and glucose intolerance through JNK/MAPK in mice. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	6
86	Severe hyperlipidemia pancreatitis induced by taking tamoxifen after breast cancer surgeryâ€”Case report. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
87	Non-metabolic causes of steatotic liver disease. , 0, 3, .		2